Renal cell carcinoma-induced immunosuppression: an immunophenotypic study of lymphocyte subpopulations and circulating dendritic cells.
Camillo Porta(University of Pavia), B. Rovereto, Chiara Villa(Centre National de la Recherche Scientifique), Patrizia Morbini(University of Pavia), Chiara Paglino, Beatrice Lillaz(University of Turin), Ilaria Imarisio(University of Pavia), B. Rovati, Lucia Bonomi, Marco Danova(Azienda Socio Sanitaria Territoriale di Pavia), Mario Mensi
PubMed
March 29, 2007
Cited by 35
Related Papers
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
|The Lancet Oncology|2012|550
Clinical Characteristics and Therapeutic Responses in Patients with Germ-Line<i>AIP</i>Mutations and Pituitary Adenomas: An International Collaborative Study
|The Journal of Clinical Endocrinology & Metabolism|2010|374
From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal
|Endocrine Related Cancer|2017|357
Gigantism and Acromegaly Due to Xq26 Microduplications and <i>GPR101</i> Mutation
|New England Journal of Medicine|2014|340